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Radiotherapy plays a central role in the local control of breast cancer following conservative surgery,
representing the standard treatment for patients undergoing quadrantectomy or lumpectomy and
consisting in 5 or 6 weeks of treatment with a total dose of 45e50 Gy.
In the last ten years new trends in radiation therapy have been developing with a new planning of
duration and extension of breast tissue to irradiate.
Moreover some authors presented the idea of combining the use of intraoperatory radiotherapy with
the partial breast irradiation, with the aim of irradiate the breast in a single session during breast
conserving surgery.
From September 2009 to July 2010 we prospectively enrolled 13 patients to undergo electron beam
intraoperative radiotherapy after breast conservative treatment for early breast cancer.
At a mean follow-up of 46 months no local recurrences have been described and no patients presented
distant metastasis or died for any cause. 6 patients (46.2%) presented complications, as ﬁbrosis and
liponecrosis.
Our results suggest that electron beam intraoperative radiotherapy in the conservative treatment of
breast cancer could be considered a suitable option for low risk patients, even if our sample is very small
and we need longer follow-up to draw conclusive results.
© 2014 Published by Elsevier Ltd on behalf of Surgical Associates Ltd.1. Introduction
Breast cancer represents 10.4% of all cancers in women, being
the second most common non-cutaneous cancer after lung cancer
and the ﬁfth cause of death [1].
Every year in Italy, around 40,000 women have a diagnosis of
breast cancerand60%of all breast cancers arediagnosed inearly stage,
thanks to the widespread use of mammographic screening [2e4].
Therefore an appropriate management of early breast cancer
results mandatory.
Since Veronesi’s Milan trial in 1981 [5] and many other inter-
national phase III trials [6e10] conﬁrmed the central role of
radiotherapy in the local control of breast cancer followingf of Surgical Associates Ltd.conservative surgery, the standard treatment for patients under-
going quadrantectomy or lumpectomy for breast cancer is repre-
sented by 5 or 6 weeks of radiotherapy with a total dose of
45e50 Gy (1.8e2 Gy for fraction).
All studies showed lowshort-term complications rates related to
radiotherapy even when conducted before the introduction of
modern radiotherapic techniques with tridimensional planning,
intensity-modulationandgated-radiotherapy for left breast cancers.
Adjuvant radiotherapy not only reduces local recurrences but
determines a better overall survival [11,12].
On the other hand, many women candidates to radiotherapy
after breast conservative surgery do not indeed undergo radiation
therapy or prefer a radical surgery because of logistic or job-related
difﬁculties in attending 6 weeks of therapy [13e17].
From 10 to 80% of all women undergoing breast conservative
surgery really perform radiotherapy as an adjuvant treatment
[18,19].
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have been developing with a new planning of duration of the
treatment and extension of breast tissue to irradiate.
According to recent studies, the total duration of radiation
treatment could be reduced to a half or a third, following different
fractioning with an augmentation of the single dose for application
and reduction of the fractions [20e22].
Moreover, according to the evidence that 85% of local re-
currences present at the level of the same quadrant of the index
cancer, partial breast irradiation (PBI) has being widely applicated,
reducing the application ﬁelds from the whole breast to the area of
the cancer.
Since about ten years some authors presented the idea of
combining the use of intraoperatory radiotherapy (that is radiation
therapy delivered during the surgery in the operating theatre) with
the partial breast irradiation, with the aim of irradiate the breast in
a single session during breast conserving surgery.
Electron beam intraoperative radiotherapy releases a single
dose of radiation for a duration of 3 min directly on the cancer ﬁeld
following quadrantectomy or lumpectomy using a linear acceler-
ator directly in the operation theatre, completely equivalent to the
entire dose of an external beam six-week fractionated
radiotherapy.
2. Material and methods
After obtaining our institution's ethical committee approval,
from September 2009 to July 2010 we prospectively enrolled 13
patients to undergo electron beam intraoperative radiotherapy af-
ter breast conservative treatment for early breast cancer.
We enrolled our patients according to the following inclusion
criteria: post-menopausal women younger than 75 (menopause
was deﬁned as: amenorrhea for more than 6 months if older than
50; amenorrhea for more than 12 months if younger than 50;
bilateral oophorectomy; if submitted to hysterectomy: menopause
if older than 50, serological conﬁrmation if younger than 50);
cytological diagnosis of breast invasive ductal carcinoma; uni-
centricity and unifocality of the disease (at magnetic resonance
imaging); no evidence of distant metastasis (at bone scintigraphy
and total body CT scan); ultrasonographic diameter of the lesion
less than 2.5 cm; negative sentinel lymph node biopsy.
Detailed information about the study was given to each patient
and written informed consent form was signed by each woman
enrolled.
Patients have been excluded from our study if: cytological
diagnosis of a different breast carcinoma histotype; skin inﬁltrating
cancer; cancer at the level of the breast axillary tail; diseases that
contraindicate radiation therapy, as connective tissue diseases,
previous thoracic irradiation, etc.)
2.1. Surgical and radiotherapic technique
All patients underwent quadrantectomy and sentinel lymph
node biopsy (SLNB). SLNB was performed through the same sur-
gical access used for the tumor excision for cancers localized at the
upper outer quadrant and through a separate skin incision for other
localizations. Sentinel lymph node was histologically examined
intraoperatively. If positive for metastatic cells, the patient would
not be submitted to intraoperative radiotherapy and excluded from
the study. Surgical excision margins around the cancer were always
at least 1 cm. Margins never resulted inﬁltrated at deﬁnitive his-
tology and the deﬁnitive histological examination of the sentinel
lymph node always conﬁrmed the intraoperative diagnosis.
Cancer grading was evaluated according to Elston and Ellis score
[23] and peri-tumoral vascular invasion according to Rosen [24].Immunohistochemical evaluation of estrogen and progesterone
receptors, Ki-67 (with monoclonal antibody MIB 1) and c-erb B2
expression was assessed for each patient.
After removing the cancer with adequate surgical margins, re-
sidual glandular tissue was mobilized from the fascia of the pec-
toralis major muscle for at least 5e10 cm around the tumor bed in
order to better approximate the breast parenchyma to the center of
the incision and expose the residual gland to the radiation beam.
Superﬁcial margin of the breast parenchyma was mobilized for
4e5 cm in every direction around the tumor bed.
In order to minimize the dose of radiation delivered to the
thoracic wall and to guarantee the release of the entire radiation
dose to the gland, a dedicated lead 5 mm thick disk (available in
different diameters (4, 5, 6, 8 and 10 cm)) was positioned between
the gland and pectoralis major muscle. In order to guarantee an
optimal chest wall protection, the disk must be larger than the area
to irradiate.
The gland was then temporarily approximate to better expose
the exact parenchyma to the radiation beam, avoiding dish-
omogeneity in the target volume shape, after positioning the pro-
tection disk under the gland.
The energy of the electron beam was chosen in relation to the
target volume thickness.
The isolation of the skin from the collimator results fundamental
in order to avoid skin irradiation. If the skin would come into direct
contact with the polymethyl methacrylate (Perspex; Hitesys SpA,
Aprilia, Italy) collimator, its margins would receive 5% of the total
dose. A dedicated device was used to completely separate the skin
from the radiation area, consisting of a metallic ring of variable
diameter connected to small nontraumatic metallic hooks. Alter-
natively the skin margins were protected with wet sterile gauzes
inserted between the skin and the collimator, creating a barrier able
to absorb the low-energy electrons scattered around the collimator
edge.
After these procedures, the sterile collimator of the linear
accelerator (LINAC) was placed in the right position in order to
guarantee the complete coverage of the target volume.
The glandular portion to be irradiated (clinical target volume) is
an area of 4e6 cm of diameter around the tumor bed but, according
to the breast volume and the technical possibility of mobilizing the
residual gland, it is possible to irradiate up to 10 cm of glandular
parenchyma.
The diameter of the collimator is chosen according to the
diameter of the area to irradiate in order to cover the entire tumor
bed and a safety margin (at least 2 cm in all directions).
The applicator was then placed into direct contact with the
breast gland, moving the LINAC through a dedicated remote
controller.
It is important to avoid herniation of part of the gland into the
collimator resulting in an increase of the dose to the superﬁcial part
of the target (with this aim a perspex disk was positioned over the
gland to irradiate and was adapted to the terminal part of the
applicator).
After positioning the applicator, 3 mobile barriers were posi-
tioned around the operating table (lead thickness 1.5 cm, height
150 cm and width 100 cm) and under the table (mobile trolley with
a lead portion of 1.5 cm in thickness) to guarantee a good shielding
of x-rays scattered by the patient.
All personel left the operating theatre and irradiation was
started through the control panel.
The irradiation was performed in two consecutive steps, in each
of which half of the dose was delivered. An in-vivo dosimetry was
performed with a dedicated dosimeter with an electronic device
placed just under the perspex disk at the terminal surface of the
applicator in order to control the dose released to the patient.
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through four energy levels of electrons (3, 5, 7 and 9 MeV).
The entire radiation procedure was completed in 2e4 min.
After delivering the radiation dose, the applicator was removed
and the LINAC moved out of the operating table. The stitches used
to approximate the breast parenchymawere partially or completely
removed in order to eliminate the protection disk. The parenchyma
was then reapproximated and the skin incision sutured with non-
absorbable material.
3. Results
Patients’mean agewas 59 years (range 50e72). All womenwere
affected by monofocal breast invasive ductal carcinoma (mono-
focality at magnetic resonance imaging and cytological diagnosis of
breast carcinoma) less than 2.5 cm in diameter (mean diameter
1.56 cm, range 0.8e2.3 cm).
Adjuvant medical treatments were prescribed according to
protocols in use in the Oncology Department of our Hospital. 8
patients (61.5%) received hormone therapy only, 1 (7.7%) chemo-
therapy only, 4 (30.8%) both adjuvant treatments. 5 patients also
underwent immunotherapy with Trastuzumab.
Follow-up was performed according to the study protocol: after
15 days from the procedure all patients were evaluated by a
multidisciplinary team (composed by an oncologist, a radiothera-
pist and a surgeon) in order to deﬁne the adjuvant treatments to
perform and to ﬁrst clinically evaluate the area submitted to IORT.
All patient were then directed to oncological, radiotherapic and
surgical follow-up in order to evaluate the loco-regional conditions
in terms of: short-term and long-term complications, cosmetic
results and oncological outcomes (local recurrence and overall
survival).
Follow-up visits were performed at one month from the pro-
cedure and then at 3, 6 and 12 months; after the ﬁrst year all
women have been followed-up each 6 months until the 5th year.
At December 2013mean follow-upwas 46months (range 41e51
months).
No patients were lost to follow-up.
All patients at follow-up visits have been evaluated using the
RTOG/EORTC scale to detect short- and long-term complications
[25].
6 patients (46.2%) presented complications. 1 patient (7.7%)
presented hematoma in the immediate postoperative period. The
same patient then presented severe ﬁbrosis. Two patients (15.4%)
presented moderate ﬁbrosis. Fibrosis presentation was progressive
in the months after the procedure, reaching the acme at one year
after the procedure and then remaining stable. These 3 patients
presented a slight skin retraction, affecting the cosmetic result. 3
patients (23.1%) presented liponecrosis from the fourth-ﬁfth post-
operative day to the tenth-eleventh day. We found this complica-
tion in women with large and adipose breasts.
Asymptomatic ﬁndings of liponecrosis at surveillance
mammography were found in 4 patients (30.8%), while ultrasono-
graphical images of non univocal interpretation have been found in
3 patients (23.1%). These ﬁndings lead to second-level procedures
as ultrasound-guided ﬁne-needle aspiration cytology (US-FNAC) to
conﬁrm the nature of the lesion (conﬁrmed to be benign).
No local recurrences have been described at the last follow up of
December 2013 and no patients presented distant metastasis or
died for any cause.
4. Discussion
Our results suggest that electron beam intraoperative radio-
therapy in the conservative treatment of breast cancer could beconsidered a suitable option for low risk patients, even if our
sample is very small and we need longer follow-up to draw
conclusive results.
Local control of disease through breast conserving surgery and
intraoperative radiotherapy remains to be deﬁned and long-term
complications, as severe ﬁbrosis or liponecrosis could compro-
mise cosmetic results, leading to reduced satisfaction levels and
worst quality of life for breast cancer patients. Moreover long-term
complications could impact on mammographic and ultrasono-
graphic postoperative surveillance, with higher need of second-
level exams due to suspect ﬁndings with obvious negative psy-
chologic and economic implications.
Many international scientiﬁc societies, as the German Society
for Radiation Oncology (DEGRO) do not consider IORT as a gold
standard as adjuvant treatment for breast cancer.
Therefore IORT should remain a treatment to be used only in
experimental studies and research projects.
DEGRO encourages further studies investigating IORT and other
partial breast irradiation methods as potentially useful options in
selected groups of patients with a well deﬁned low-risk proﬁle
[26e30].
In contrast with these considerations, the American Society for
Therapeutic Radiology and Oncology (ASTRO) [31] and the Euro-
pean Society for Therapeutic Radiology and Oncology (ESTRO)
[31e33] published recommendations for clinical practice in guiding
the selection of patients for partial breast irradiation outside from
clinical trials. These indications have been criticized by the Amer-
ican Scientiﬁc Community [34] and have not been adopted byNCCN
(National Comprehensive Cancer Network) [35].
ASTRO deﬁnes three groups for the use of patients for partial
breast irradiation (PBI): “suitable”, “to use with caution”, “unsuit-
able” [34].
PBI is considered to be acceptable outside from a clinical trial
only for “suitable” patients, represented by patients older than 60
years, with negative lymph nodes, T1 cancers, estrogen receptors
positive, no lymphovascular invasion, surgical margins wider than
2 mm and no multicentricity.
Recently published data from the group of Orecchia [36] showed
that intraoperative radiotherapy with electrons resulted in signiﬁ-
cantly higher local recurrence than did conventional postoperative
external radiotherapy after 5 years of follow-up suggesting that
intraoperative radiotherapy with electrons should be restricted to
suitable patients only, once characteristics deﬁning suitability have
been deﬁned.
In conclusion whole breast irradiation as adjuvant therapy
following breast conservative surgery remains the gold standard,
basing on well deﬁned results in terms of local control of disease,
acceptable cosmetic results and low toxicity.
The use of a new technique of partial breast irradiation as
standard adjuvant treatment after or during breast conserving
surgery will be possible only if this new technique will be equal or
better than whole breast irradiation in terms of efﬁcacy, impact on
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